Convalo Health - Neue Erfolgsstory des ehemaligen CEOs von Patient Home Monitoring (TSXV:PHM) - 500 Beiträge pro Seite
eröffnet am 17.03.15 20:20:43 von
neuester Beitrag 30.09.15 21:01:34 von
neuester Beitrag 30.09.15 21:01:34 von
Beiträge: 32
ID: 1.209.596
ID: 1.209.596
Aufrufe heute: 0
Gesamt: 16.994
Gesamt: 16.994
Aktive User: 0
ISIN: CA9230102019 · WKN: A2PE0H
0,5510
EUR
-1,78 %
-0,0100 EUR
Letzter Kurs 22.03.19 Frankfurt
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,8300 | +161,43 | |
| 9,2900 | +20,96 | |
| 111,75 | +18,87 | |
| 1,0900 | +14,74 | |
| 1,7000 | +13,33 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5058 | -12,79 | |
| 9,7200 | -19,60 | |
| 14,510 | -32,32 | |
| 8,0000 | -36,76 | |
| 1.160,00 | -42,00 |
Feedback
Aktie zieht unter starkem Volumen an. Akquisitionen ante portas. Bin mal long.
PHM ging von 0,28 auf mittlerweile 1,36 CAD.
Michael Dalsin - Chairman and CEO: Chairman and Former CEO of Patient Home Monitoring (TSXV:PHM), former Managing Director of Stanmore Capital Partners, a healthcare services investment group founded in 2002. Previous to Stanmore, Mr. Dalsin worked in international investment banking and deal-making in London, Hong Kong and New York. He has participated as a lead banker and negotiator for a number of small and medium market ($25M to $100M) international roll-ups for both American and English companies. He holds an economics degree from University of Wisconsin - Madison.
Mehr Infos auf http://www.convalohealth.com/
PHM ging von 0,28 auf mittlerweile 1,36 CAD.
Michael Dalsin - Chairman and CEO: Chairman and Former CEO of Patient Home Monitoring (TSXV:PHM), former Managing Director of Stanmore Capital Partners, a healthcare services investment group founded in 2002. Previous to Stanmore, Mr. Dalsin worked in international investment banking and deal-making in London, Hong Kong and New York. He has participated as a lead banker and negotiator for a number of small and medium market ($25M to $100M) international roll-ups for both American and English companies. He holds an economics degree from University of Wisconsin - Madison.
Mehr Infos auf http://www.convalohealth.com/
Bin mal mit 'ner Anfangsposi dabei ... CEO scheint ja was auf die Beine stellen zu können 
Und schon im Plus
Und schon im Plus
Zurück auf Start ... war gestern zwischenzeitlich ( ATH ) mal knapp 10 % im Plus. ;-)
CONVALO HEALTH INTERNATIONAL, CORP. ANNOUNCES $7.5 MILLION BOUGHT DEAL FINANCING
Convalo Health International Corp. has entered into an agreement with a syndicate of underwriters led by Mackie Research Capital Corp. and including Beacon Securities Ltd., whereby the underwriters will purchase, on a bought-deal basis, 18.75 million units of Convalo at a price of 40 cents per unit for gross proceeds to Convalo of $7.5-million.
Each Unit will consist of one (1) common share (a "Common Share") in the capital of Convalo and one (1) warrant (a "Warrant") of Convalo. Each Warrant entitles the holder thereof to acquire one Common Share for an exercise price of $0.50 per Common Share for a period of 36 months following closing of the Offering (the "Closing"). The expiry date of the Warrants may be accelerated by Convalo at any time following the six-month anniversary of the Closing and prior to the expiry date of the Warrants if the volume-weighted average trading price of the Common Shares is greater than $0.60 for any 20 consecutive trading days.
The Company has granted the Underwriters an option (the "Agent's Option") to increase the size of the Offering by up to an additional 15% of the total number of Units to be issued under the Offering, at any time on or before 48 hours prior to the Closing.
The Offering is scheduled to close on or about the week of April 20, 2015 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals including the approval of the TSX Venture Exchange. The securities to be issued under the Offering will have a hold period of four months from the Closing. The net proceeds from the Offering will be used by Convalo for acquisition purposes and general working capital.
In consideration for their services, the Underwriters will receive a cash commission of 5.0% of the gross proceeds of the Offering, and shall receive such number of compensation options exercisable into Units, as is equal to 5.0% of the Units issued pursuant to the Offering.
Convalo Health International Corp. has entered into an agreement with a syndicate of underwriters led by Mackie Research Capital Corp. and including Beacon Securities Ltd., whereby the underwriters will purchase, on a bought-deal basis, 18.75 million units of Convalo at a price of 40 cents per unit for gross proceeds to Convalo of $7.5-million.
Each Unit will consist of one (1) common share (a "Common Share") in the capital of Convalo and one (1) warrant (a "Warrant") of Convalo. Each Warrant entitles the holder thereof to acquire one Common Share for an exercise price of $0.50 per Common Share for a period of 36 months following closing of the Offering (the "Closing"). The expiry date of the Warrants may be accelerated by Convalo at any time following the six-month anniversary of the Closing and prior to the expiry date of the Warrants if the volume-weighted average trading price of the Common Shares is greater than $0.60 for any 20 consecutive trading days.
The Company has granted the Underwriters an option (the "Agent's Option") to increase the size of the Offering by up to an additional 15% of the total number of Units to be issued under the Offering, at any time on or before 48 hours prior to the Closing.
The Offering is scheduled to close on or about the week of April 20, 2015 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals including the approval of the TSX Venture Exchange. The securities to be issued under the Offering will have a hold period of four months from the Closing. The net proceeds from the Offering will be used by Convalo for acquisition purposes and general working capital.
In consideration for their services, the Underwriters will receive a cash commission of 5.0% of the gross proceeds of the Offering, and shall receive such number of compensation options exercisable into Units, as is equal to 5.0% of the Units issued pursuant to the Offering.
Convalo to buy two L.A. firms for $250,000, 1.3M shares
2015-03-30 20:32 ET - News Release
Mr. Michael Dalsin reports
CONVALO HEALTH INTERNATIONAL, CORP. OPENS SECOND LOCATION IN THE LOS ANGELES MARKET; EXPANDS M&A PLAN AND UPDATES PIPELINE
Convalo Health International Corp.'s board of directors has approved the execution of purchase agreements to acquire the stock of two companies with a focus on referral-based addiction-related services on the west side of Los Angeles.
Expanded M&A (merger and acquisitions) plan
Convalo announced it has expanded its M&A strategy since listing on Feb. 17, 2015, on the TSX Venture Exchange. Convalo is now concentrating on four types of acquisition targets in the market:
Medical detox centres;
Referral-based outpatient centres;
Residential treatment centres;
Criminal-justice-oriented treatment and education centres.
All acquisition targets are small, locally owned treatment, medical or education centres offering addiction-related services and specializing in a singular service or market. Convalo plans to increase revenues organically through offering a full suite of services in larger, luxury facilities upgraded to the highest level of licensing and certifications on a nationwide basis.
Convalo has hired a staff of four M&A professionals and analysts since listing and is actively working to contact and qualify over 1,000 identified targets fitting the target descriptions. There are over 16,000 licensed treatment centres in a highly fragmented market in the United States.
Pipeline
Since Feb. 17, 2015, the active pipeline of potential acquisition targets has grown to:
Three companies in advanced discussions with trailing 12-month cash flow in between $1-million and $1.5-million;
Seven additional companies under non-disclosure agreements (NDA).
All potential targets are local companies that range in geography across the United States, from New York to Florida to California. The companies offer services ranging from treatment services under contract with criminal justice systems to reduce prison overcrowding, to high-luxury treatment centres, to medical detox clinics strictly focused on medical services.
West Los Angeles market acquisitions and new centre opening
Convalo has an agreement to acquire two companies that have historically referred a combined 15 clients per month for outpatient addiction treatment, with potential revenues of up to $200,000 per month for the new facility. Concurrently, Convalo has executed a lease for a luxury 5,772-square-foot facility on the west side of Los Angeles near Venice Beach, Culver City and Santa Monica. The centre can also serve the large treatment population in Malibu, Calif.
This acquisition is similar to the Hollywood centre acquisition in 2014. The centre will also operate under the BLVD Treatment Centers brand name. In June, 2014, the Hollywood centre had revenues of less than $62,000 for the month. As part of the five-point postacquisition organic revenue growth plan, operational, facility and marketing improvements were made that resulted in combined unaudited revenues for January and February of over $675,000 with operational profit(1) in excess of $100,000. The centre was at 45-per-cent capacity for the months of January and February, 2015.
The new west Los Angeles facility is expected to be fully operational by summertime and is expected to generate revenue growth similar to the Hollywood operation, with a capacity of up to 100 clients per month.
Under the agreement, Convalo will issue 1.35 million shares to the owners of the companies, restricted for 24 months, and $250,000 in cash. The active shareholders of the companies will join BLVD Centers. The closing of the acquisitions is subject to exchange approval.
Audited financials on SEDAR
Convalo also released audited financial statements on SEDAR for the full year ended Nov. 30, 2014. As a result of the recent listing on the TSX Venture Exchange, the company was required to provide audited financial results for the full fiscal year ended Nov. 30, 2014. For the period of the audit, Convalo operated one centre in Hollywood under the BLVD Treatment Centers brand, launching the full 100-client-capacity centre on Nov. 1, 2014. Through the listing process, Convalo had already provided audited financial statements for the first three quarters of fiscal 2014 of limited, preacquisition operations.
"Since listing just a month ago, we have invested heavily in our M&A team and pipeline," said Michael Dalsin, chairman and chief executive officer of Convalo. "We have expanded our focus to three additional types of addiction-related service companies for acquisition. I believe this market is ripe for consolidation and we are in a very good position to be one of the most active players in the market.
"Launching the new outpatient treatment centre in west Los Angeles is a key part of our growth strategy," continued Mr. Dalsin. "I do expect we will acquire and launch more outpatient centres in other U.S. cities this year, along with acquisitions of other types of addiction-related businesses. As we make these acquisitions, I expect we will continue to see the tremendous organic revenue growth we have experienced at the Hollywood location."
2015-03-30 20:32 ET - News Release
Mr. Michael Dalsin reports
CONVALO HEALTH INTERNATIONAL, CORP. OPENS SECOND LOCATION IN THE LOS ANGELES MARKET; EXPANDS M&A PLAN AND UPDATES PIPELINE
Convalo Health International Corp.'s board of directors has approved the execution of purchase agreements to acquire the stock of two companies with a focus on referral-based addiction-related services on the west side of Los Angeles.
Expanded M&A (merger and acquisitions) plan
Convalo announced it has expanded its M&A strategy since listing on Feb. 17, 2015, on the TSX Venture Exchange. Convalo is now concentrating on four types of acquisition targets in the market:
Medical detox centres;
Referral-based outpatient centres;
Residential treatment centres;
Criminal-justice-oriented treatment and education centres.
All acquisition targets are small, locally owned treatment, medical or education centres offering addiction-related services and specializing in a singular service or market. Convalo plans to increase revenues organically through offering a full suite of services in larger, luxury facilities upgraded to the highest level of licensing and certifications on a nationwide basis.
Convalo has hired a staff of four M&A professionals and analysts since listing and is actively working to contact and qualify over 1,000 identified targets fitting the target descriptions. There are over 16,000 licensed treatment centres in a highly fragmented market in the United States.
Pipeline
Since Feb. 17, 2015, the active pipeline of potential acquisition targets has grown to:
Three companies in advanced discussions with trailing 12-month cash flow in between $1-million and $1.5-million;
Seven additional companies under non-disclosure agreements (NDA).
All potential targets are local companies that range in geography across the United States, from New York to Florida to California. The companies offer services ranging from treatment services under contract with criminal justice systems to reduce prison overcrowding, to high-luxury treatment centres, to medical detox clinics strictly focused on medical services.
West Los Angeles market acquisitions and new centre opening
Convalo has an agreement to acquire two companies that have historically referred a combined 15 clients per month for outpatient addiction treatment, with potential revenues of up to $200,000 per month for the new facility. Concurrently, Convalo has executed a lease for a luxury 5,772-square-foot facility on the west side of Los Angeles near Venice Beach, Culver City and Santa Monica. The centre can also serve the large treatment population in Malibu, Calif.
This acquisition is similar to the Hollywood centre acquisition in 2014. The centre will also operate under the BLVD Treatment Centers brand name. In June, 2014, the Hollywood centre had revenues of less than $62,000 for the month. As part of the five-point postacquisition organic revenue growth plan, operational, facility and marketing improvements were made that resulted in combined unaudited revenues for January and February of over $675,000 with operational profit(1) in excess of $100,000. The centre was at 45-per-cent capacity for the months of January and February, 2015.
The new west Los Angeles facility is expected to be fully operational by summertime and is expected to generate revenue growth similar to the Hollywood operation, with a capacity of up to 100 clients per month.
Under the agreement, Convalo will issue 1.35 million shares to the owners of the companies, restricted for 24 months, and $250,000 in cash. The active shareholders of the companies will join BLVD Centers. The closing of the acquisitions is subject to exchange approval.
Audited financials on SEDAR
Convalo also released audited financial statements on SEDAR for the full year ended Nov. 30, 2014. As a result of the recent listing on the TSX Venture Exchange, the company was required to provide audited financial results for the full fiscal year ended Nov. 30, 2014. For the period of the audit, Convalo operated one centre in Hollywood under the BLVD Treatment Centers brand, launching the full 100-client-capacity centre on Nov. 1, 2014. Through the listing process, Convalo had already provided audited financial statements for the first three quarters of fiscal 2014 of limited, preacquisition operations.
"Since listing just a month ago, we have invested heavily in our M&A team and pipeline," said Michael Dalsin, chairman and chief executive officer of Convalo. "We have expanded our focus to three additional types of addiction-related service companies for acquisition. I believe this market is ripe for consolidation and we are in a very good position to be one of the most active players in the market.
"Launching the new outpatient treatment centre in west Los Angeles is a key part of our growth strategy," continued Mr. Dalsin. "I do expect we will acquire and launch more outpatient centres in other U.S. cities this year, along with acquisitions of other types of addiction-related businesses. As we make these acquisitions, I expect we will continue to see the tremendous organic revenue growth we have experienced at the Hollywood location."
Trading Spotlight
CONVALO HEALTH INTERNATIONAL, CORP. ANNOUNCES INCREASE OF PREVIOUSLY ANNOUNCED BOUGHT DEAL FINANCING TO $15 MILLION
Convalo Health International Corp., in connection with its previously announced bought-deal private placement offering, has entered into an amendment agreement with Mackie Research Capital Corp., as lead underwriter, and Beacon Securities Ltd. to upsize the offering from $7.5-million to $15-million. The underwriters have agreed to purchase, on a bought-deal basis, 37.5 million units of the company at a price of 40 cents per unit, for gross proceeds to the company of $15-million.
Each unit will consist of one common share in the capital of Convalo and one warrant of Convalo. Each warrant entitles the holder thereof to acquire one common share for an exercise price of 50 cents per common share for a period of 36 months following closing of the offering. The expiry date of the warrants may be accelerated by Convalo at any time following the six-month anniversary of the closing, and prior to the expiry date of the warrants, if the volume-weighted average trading price of the common shares is greater than 60 cents for any 20 consecutive trading days.
The company has granted the underwriters an option to increase the size of the offering by up to an additional 15 per cent of the total number of units to be issued under the offering, at any time on or before 48 hours prior to the closing.
The offering is scheduled to close on or about the week of April 20, 2015, and is subject to certain conditions, including but not limited to, the receipt of all necessary approvals including the approval of the TSX Venture Exchange. The securities to be issued under the offering will have a hold period of four months and one day from the closing. The net proceeds from the offering will be used by Convalo for acquisition purposes and general working capital.
Convalo Health International Corp., in connection with its previously announced bought-deal private placement offering, has entered into an amendment agreement with Mackie Research Capital Corp., as lead underwriter, and Beacon Securities Ltd. to upsize the offering from $7.5-million to $15-million. The underwriters have agreed to purchase, on a bought-deal basis, 37.5 million units of the company at a price of 40 cents per unit, for gross proceeds to the company of $15-million.
Each unit will consist of one common share in the capital of Convalo and one warrant of Convalo. Each warrant entitles the holder thereof to acquire one common share for an exercise price of 50 cents per common share for a period of 36 months following closing of the offering. The expiry date of the warrants may be accelerated by Convalo at any time following the six-month anniversary of the closing, and prior to the expiry date of the warrants, if the volume-weighted average trading price of the common shares is greater than 60 cents for any 20 consecutive trading days.
The company has granted the underwriters an option to increase the size of the offering by up to an additional 15 per cent of the total number of units to be issued under the offering, at any time on or before 48 hours prior to the closing.
The offering is scheduled to close on or about the week of April 20, 2015, and is subject to certain conditions, including but not limited to, the receipt of all necessary approvals including the approval of the TSX Venture Exchange. The securities to be issued under the offering will have a hold period of four months and one day from the closing. The net proceeds from the offering will be used by Convalo for acquisition purposes and general working capital.
No brainer
1,50 CAD bis Ende Juni 2015
1,50 CAD bis Ende Juni 2015
Schlusskurs am Ostermontag: 0,59 CAD
+18 Prozent
Advanced Proteome (APC.V) finde ich auch sehr spannend.
+18 Prozent
Advanced Proteome (APC.V) finde ich auch sehr spannend.
Wenn ich die Insidertransaktionen bei PHM so sehe, würde ich darauf wetten, dass zwei Direktoren von PHM in das Private Placement von CXV umschichten.
Aktuell 0,63 CAD.
Aktuell 0,63 CAD.
PHM und CXV im BNN Market Call
http://www.bnn.ca/Video/player.aspx?vid=586799 ;-)
Der Wert geht ja mächtig ab !!!
Luft holen zum nächsten Anstieg ... ;-)
Luft holen zum nächsten Anstieg ... ;-)
Neues Intraday Allzeithoch bei 0,74 CAD.
Es läuft ;-)
Es läuft ;-)
Gestern wurden 14,3 Mio. Aktien gehandelt. Ich wage mal die These, dass wir Distribution sehen und die Aktie bald den Rückwärtsgang einlegen wird. Ich habe mir das Modell mal angesehen und kann die Euphorie nur bedingt nachvollziehen. Natürlich ist Potenzial vorhanden, aber das muss auch erst mal umgesetzt werden. Die Aktie läuft aus meiner Sicht viel zu schnell - wie es gerade bei vielen TSX-Werten der Fall ist.
M@trix
M@trix
Irrtum. Schwerer Irrtum. ;-)
Antwort auf Beitrag Nr.: 49.533.896 von techinvestor69 am 10.04.15 10:23:34Hmmm... möglich. Aber Börsenwert 70 Mio. CAD ist schon ein Wort. Immerhin hat man ja gerade erst angefangen, das Konzept umzusetzen.
Heute übrigens schon wieder 3,2 Mio. Aktien gehandelt. Seit Februar wurde sicher der gesamte Free Float schon ein bis zwei mal "gedreht".
Gefällt mir nicht. Kurzfristig ist zwar vieles möglich (siehe NPH), doch letztlich bin ich kein Trader, sondern Investor. Und bei CXV wird schon einiges an Entwicklung der nächsten 12 Monate eingepreist.
M@trix
P.S. Dennoch danke für deine vielen Anregungen auf der Aktienseite. Advanced Proteome halte ich z.B. für sehr spannend und habe den Wert mal auf die WL genommen.
Heute übrigens schon wieder 3,2 Mio. Aktien gehandelt. Seit Februar wurde sicher der gesamte Free Float schon ein bis zwei mal "gedreht".
Gefällt mir nicht. Kurzfristig ist zwar vieles möglich (siehe NPH), doch letztlich bin ich kein Trader, sondern Investor. Und bei CXV wird schon einiges an Entwicklung der nächsten 12 Monate eingepreist.
M@trix
P.S. Dennoch danke für deine vielen Anregungen auf der Aktienseite. Advanced Proteome halte ich z.B. für sehr spannend und habe den Wert mal auf die WL genommen.
Die ganzen 90 Tage warrants werden ausgeübt. Der Firma fließt das Geld für Akquisitionen zu. Wie sollen sie ohne Geld eine M&A Strategie fahren? Nicht jeder nimmt Aktien als Bezahlung.
NPH war nur ein US-Push. Bei CXV kaufen die Profis.
NPH war nur ein US-Push. Bei CXV kaufen die Profis.
Kampf mit dem 52 Wochen Hoch.
gestern neues 52-Wochen Hoch markiert und auch auf dem Hoch geschlossen.
Dollar - wir kommen!
Dollar - wir kommen!
Chart - einfach Wahnsinn 
Vodis läuft auch schon gut an
Vodis läuft auch schon gut an
CONVALO HEALTH INTERNATIONAL, CORP. CLOSES $17.25 MILLION BOUGHT DEAL FINANCING
Convalo Health International Corp. has closed its previously announced bought-deal private placement offering. Mackie Research Capital Corp. was lead underwriter and sole bookrunner on behalf of a syndicate of underwriters including Beacon Securities Ltd., whereby the underwriters purchased 43,125,000 units of the company at a price of 40 cents per unit, for gross proceeds to the company of $17.25-million, which included the full exercise of the overallotment option of 5,625,000 units.
The securities issued under the offering are subject to a hold period, which will expire four months and one day from the date of closing, being Aug. 23, 2015. The net proceeds from the offering will be used by Convalo for acquisition purposes and general working capital.
In consideration for their services, the underwriters received a cash commission of 5.0 per cent of the gross proceeds of the offering, and have received such number of compensation options exercisable into units, as is equal to 5.0 per cent of the units issued in the offering.
Quelle: http://www.stockwatch.com/News/Item.aspx?bid=Z-C:CXV-2269697…
Convalo Health International Corp. has closed its previously announced bought-deal private placement offering. Mackie Research Capital Corp. was lead underwriter and sole bookrunner on behalf of a syndicate of underwriters including Beacon Securities Ltd., whereby the underwriters purchased 43,125,000 units of the company at a price of 40 cents per unit, for gross proceeds to the company of $17.25-million, which included the full exercise of the overallotment option of 5,625,000 units.
The securities issued under the offering are subject to a hold period, which will expire four months and one day from the date of closing, being Aug. 23, 2015. The net proceeds from the offering will be used by Convalo for acquisition purposes and general working capital.
In consideration for their services, the underwriters received a cash commission of 5.0 per cent of the gross proceeds of the offering, and have received such number of compensation options exercisable into units, as is equal to 5.0 per cent of the units issued in the offering.
Quelle: http://www.stockwatch.com/News/Item.aspx?bid=Z-C:CXV-2269697…
Antwort auf Beitrag Nr.: 49.539.320 von M@trix am 10.04.15 18:18:01
Wie vermutet nun der "Crash" - gestern 22% nach unten bei 9 Mio. gehandelten Aktien. Denke zwischen 0,40 CAD und 0,50 CAD kann man spekulativ ein paar Aktien kaufen. Ich bleibe hier aber erst mal außen vor und warte die fundamentale Entwicklung ab. Lieber kaufe ich teurer jedoch mit bewiesenem Geschäftsmodell als "günstig" basierend auf Annahmen/Wahrscheinlichkeiten.
M@trix
Zitat von M@trix: Hmmm... möglich. Aber Börsenwert 70 Mio. CAD ist schon ein Wort. Immerhin hat man ja gerade erst angefangen, das Konzept umzusetzen.
Heute übrigens schon wieder 3,2 Mio. Aktien gehandelt. Seit Februar wurde sicher der gesamte Free Float schon ein bis zwei mal "gedreht".
Gefällt mir nicht. Kurzfristig ist zwar vieles möglich (siehe NPH), doch letztlich bin ich kein Trader, sondern Investor. Und bei CXV wird schon einiges an Entwicklung der nächsten 12 Monate eingepreist.
M@trix
P.S. Dennoch danke für deine vielen Anregungen auf der Aktienseite. Advanced Proteome halte ich z.B. für sehr spannend und habe den Wert mal auf die WL genommen.
Wie vermutet nun der "Crash" - gestern 22% nach unten bei 9 Mio. gehandelten Aktien. Denke zwischen 0,40 CAD und 0,50 CAD kann man spekulativ ein paar Aktien kaufen. Ich bleibe hier aber erst mal außen vor und warte die fundamentale Entwicklung ab. Lieber kaufe ich teurer jedoch mit bewiesenem Geschäftsmodell als "günstig" basierend auf Annahmen/Wahrscheinlichkeiten.
M@trix
Wo ist das "Klatschen"-Smiley für Matrix? 
Im Sog von PHM ging es mit nach unten.
Support bei 0,44 CAD.
Im Sog von PHM ging es mit nach unten.
Support bei 0,44 CAD.
Convalo Health International (Convalo) Announces Profitable First Full Quarter of Operations; Post-Acquisition Annualized Organic Revenue Growth of 793%
LOS ANGELES, CALIFORNIA--(Marketwired - April 29, 2015) -
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Convalo Health International, Corp. (Convalo) (TSX VENTURE:CXV), a company focused on rolling up the highly-fragmented addiction recovery sector of companies in the US, today provided highlights of its financial results for the quarter ending February 28, 2015.
Full results are available on sedar.com.
Quarter Highlights:
Convalo acquired a small referral-based company and moved into a large, fully accredited treatment center, under the brand name BLVD Treatment Centers, in June 2014. The center became fully operational November 1, 2014.
Quarterly Revenue
Revenue for the first full fiscal quarter of operations (ending February 28th, 2015) was $1,201,225.
March 2015 revenue exceeded $500,000 or over $6,000,000 annualized current run rate revenue.
Organic Growth Rate
Annualized organic growth is tracking in excess of 793% in the Hollywood Center.
Post acquisition, BLVD Treatment Centers' first full month of revenue, June 2014, was $63,000, or $756,000 annualized. By comparison, March 2015 revenues were over $6,000,000 on an annualized basis.
Quarterly Profitability
Operating income (before stock-based compensation and facility start-up costs) for the first full fiscal quarter (ending February 28th, 2015) was $242,679. (1)
Net earnings before potential tax liabilities for the quarter (including stock-based compensation and new facility start-up costs) were $153,250.
Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA), excluding new facility start-up costs, for the quarter was $245,677(2).
Balance Sheet
Cash as of April 27, 2015 was $25,689,175; Cash at the end of the quarter was $5,402,596.
Accounts Receivable at the end of the quarter of $903,355 and Accounts Payable and accrued liabilities associated with the listing process at the end of the quarter of $741,907.
Mergers & Acquisitions
Convalo has executed 17 non-disclosure agreements (NDA) since listing.
Convalo has issued 4 term sheets since listing.
"This is our first full quarter of operations after our first acquisition, and even with a full compliment of corporate overhead, we generated a nice profit," said Michael Dalsin, Chairman of Convalo. "Our organic revenue growth has certainly exceeded my expectations from when we made our first acquisition last year. The first center we acquired had a clinical focus. We made the center more appealing to our young clientele, generating stronger referrals and fueling rapid growth. I am looking forward to results from the second acquisition we made last month and am optimistic that we can enhance its offerings and continue to achieve high organic growth."
"We have over $25 million in cash and a deep pipeline of acquisition targets," continued Mr. Dalsin. "Given our balance sheet and organic growth rate, we are going to be very aggressive in making acquisitions."
Convalo will host an interactive Q&A earnings call at 4p.m. EST on Thursday, April 30, 2015 to provide in depth data and analysis about the quarterly results.
Participants from Convalo will be Michael Dalsin (Chairman) and David Ward (CFO).
The details of the call will be released shortly.
Financial professionals are invited to call in and ask questions. To pre-register as a qualified caller, please e-mail dwilson@convalohealth.com by 5 p.m. EST Wednesday, April 29th, 2015.
About Convalo
Convalo is an acquisition-oriented company focused on rolling up the US outpatient addiction rehabilitation market led by seasoned management with experience in both US healthcare acquisitions and healthcare service asset management. In 2014, Convalo made its first acquisition of a small, local addiction rehabilitation center in Los Angeles. That business has operated under the brand name BLVD Centers (www.blvdcenters.com) in a luxury Hollywood, California location. BLVD offers patients access to a wide range of services, including addictive and co-occurring disorders, helpful to the recovery process. In conjunction with the 12-Step approach, BLVD also offers supplemental insurance-reimbursed services catering to a variety of communities: gender specific, creatively-oriented, meditation/mindfulness, trauma and LGBT affirmative.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
-(1) Operating Income does not include Stock Based Compensation and new facility start up costs.
-(2)Adjusted EBITDA is defined as EBITDA plus Stock Based Compensation, excluding new facility start up cost and transaction costs.
Forward-Looking Statements
Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Convalo and anticipated events or results, are assumptions based on beliefs of Convalo's senior management as well as information currently available to it. While these assumptions were considered reasonable by Convalo at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue operations, decline of reimbursement rates, dependence on few payors, possible new drug discoveries, a novel business model, dependence on key suppliers, granting of permits and licenses in a highly regulated business, competition, difficulty integrating newly acquired businesses, low profit market segments as well as general economic, market and business conditions, and could differ materially from what is currently expected. This press release refers non-GAAP and non-IFRS financial measures that do not have standardized meaning prescribed by GAAP or IFRS. Convalo's presentation of these financial measures may not be comparable to similarly titled measures used by other companies. These financial measures are intended to provide additional information to investors concerning Convalo's performance.
Convalo Health International, Corp.
Dennis Wilson
Corporate Affairs
investorinfo@convalohealth.com
convalohealth.com
Quelle: http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e3754…
LOS ANGELES, CALIFORNIA--(Marketwired - April 29, 2015) -
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Convalo Health International, Corp. (Convalo) (TSX VENTURE:CXV), a company focused on rolling up the highly-fragmented addiction recovery sector of companies in the US, today provided highlights of its financial results for the quarter ending February 28, 2015.
Full results are available on sedar.com.
Quarter Highlights:
Convalo acquired a small referral-based company and moved into a large, fully accredited treatment center, under the brand name BLVD Treatment Centers, in June 2014. The center became fully operational November 1, 2014.
Quarterly Revenue
Revenue for the first full fiscal quarter of operations (ending February 28th, 2015) was $1,201,225.
March 2015 revenue exceeded $500,000 or over $6,000,000 annualized current run rate revenue.
Organic Growth Rate
Annualized organic growth is tracking in excess of 793% in the Hollywood Center.
Post acquisition, BLVD Treatment Centers' first full month of revenue, June 2014, was $63,000, or $756,000 annualized. By comparison, March 2015 revenues were over $6,000,000 on an annualized basis.
Quarterly Profitability
Operating income (before stock-based compensation and facility start-up costs) for the first full fiscal quarter (ending February 28th, 2015) was $242,679. (1)
Net earnings before potential tax liabilities for the quarter (including stock-based compensation and new facility start-up costs) were $153,250.
Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA), excluding new facility start-up costs, for the quarter was $245,677(2).
Balance Sheet
Cash as of April 27, 2015 was $25,689,175; Cash at the end of the quarter was $5,402,596.
Accounts Receivable at the end of the quarter of $903,355 and Accounts Payable and accrued liabilities associated with the listing process at the end of the quarter of $741,907.
Mergers & Acquisitions
Convalo has executed 17 non-disclosure agreements (NDA) since listing.
Convalo has issued 4 term sheets since listing.
"This is our first full quarter of operations after our first acquisition, and even with a full compliment of corporate overhead, we generated a nice profit," said Michael Dalsin, Chairman of Convalo. "Our organic revenue growth has certainly exceeded my expectations from when we made our first acquisition last year. The first center we acquired had a clinical focus. We made the center more appealing to our young clientele, generating stronger referrals and fueling rapid growth. I am looking forward to results from the second acquisition we made last month and am optimistic that we can enhance its offerings and continue to achieve high organic growth."
"We have over $25 million in cash and a deep pipeline of acquisition targets," continued Mr. Dalsin. "Given our balance sheet and organic growth rate, we are going to be very aggressive in making acquisitions."
Convalo will host an interactive Q&A earnings call at 4p.m. EST on Thursday, April 30, 2015 to provide in depth data and analysis about the quarterly results.
Participants from Convalo will be Michael Dalsin (Chairman) and David Ward (CFO).
The details of the call will be released shortly.
Financial professionals are invited to call in and ask questions. To pre-register as a qualified caller, please e-mail dwilson@convalohealth.com by 5 p.m. EST Wednesday, April 29th, 2015.
About Convalo
Convalo is an acquisition-oriented company focused on rolling up the US outpatient addiction rehabilitation market led by seasoned management with experience in both US healthcare acquisitions and healthcare service asset management. In 2014, Convalo made its first acquisition of a small, local addiction rehabilitation center in Los Angeles. That business has operated under the brand name BLVD Centers (www.blvdcenters.com) in a luxury Hollywood, California location. BLVD offers patients access to a wide range of services, including addictive and co-occurring disorders, helpful to the recovery process. In conjunction with the 12-Step approach, BLVD also offers supplemental insurance-reimbursed services catering to a variety of communities: gender specific, creatively-oriented, meditation/mindfulness, trauma and LGBT affirmative.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
-(1) Operating Income does not include Stock Based Compensation and new facility start up costs.
-(2)Adjusted EBITDA is defined as EBITDA plus Stock Based Compensation, excluding new facility start up cost and transaction costs.
Forward-Looking Statements
Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Convalo and anticipated events or results, are assumptions based on beliefs of Convalo's senior management as well as information currently available to it. While these assumptions were considered reasonable by Convalo at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue operations, decline of reimbursement rates, dependence on few payors, possible new drug discoveries, a novel business model, dependence on key suppliers, granting of permits and licenses in a highly regulated business, competition, difficulty integrating newly acquired businesses, low profit market segments as well as general economic, market and business conditions, and could differ materially from what is currently expected. This press release refers non-GAAP and non-IFRS financial measures that do not have standardized meaning prescribed by GAAP or IFRS. Convalo's presentation of these financial measures may not be comparable to similarly titled measures used by other companies. These financial measures are intended to provide additional information to investors concerning Convalo's performance.
Convalo Health International, Corp.
Dennis Wilson
Corporate Affairs
investorinfo@convalohealth.com
convalohealth.com
Quelle: http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e3754…
CONVALO HEALTH INTERNATIONAL (CONVALO) ANNOUNCES PLAN TO ACQUIRE TWO SOUTHERN CALIFORNIA TREATMENT COMPANIES
Convalo Health International Corp. has come to terms to acquire two profitable Southern California companies, Hollywood Detox Center and Accredited Rehab and Treatment Services (ARTS). As part of the acquisitions, Convalo will retain the three top executives in key positions at the national level, strengthening Convalo's existing management team in the area of operations, admissions and executive management. As part of the acquisition, these executives would take over operational management of the current BLVD Treatment Centers portfolio of outpatient centers.
The acquisitions, expected to close very shortly pending a final purchase agreement, provide a fully vertically integrated platform in Hollywood and, within the next year, serve as a platform for the greater Los Angeles metropolitan area, offering detox services, men's and women's residential treatment services and aftercare services in West Los Angeles subsequent to Convalo's acquisition last month of the outpatient center announced March 30th, 2015.
For the Hollywood area, the acquisition will immediately give Convalo the ability to provide services that fully encompass the entirety of the patients' needs throughout the course of recovery, resulting in improvements to overall quality of care, a higher revenue per patient, and a more fluid patient experience at every level.
The accretive acquisitions will have an immediate and positive impact on earnings per share (EPS). The final terms of the acquisitions will be announced upon the execution of the final purchase agreements. The sellers will take both stock and cash as consideration.
"With this deal, we have a full service platform in Los Angeles," said Michael Dalsin, Chairman of Convalo. "We wanted to announce this deal pre-closing to ensure that the respective staff members at BLVD Centers, ARTS and Hollywood Detox could openly work together to integrate and begin cross selling all services to clients. We plan to announce full financial details of the acquisition at closing, both in terms of expected positive impact on our annual revenues and profits, as well as the amount of cash and restricted stock paid to the sellers."
"We are particularly excited to be retaining Keith Fowler and Brent Ortner from Hollywood Detox and Ryan Newport from ARTS as senior executives of our nationwide strategy and I welcome them as future shareholders and partners in our acquisition model. We expect to have a substantial amount of cash after we close this deal and are focusing on deals in New York, San Francisco, Miami and Chicago to create a nationwide network of addiction treatment centers offering the full range of addiction services from detox all the way to aftercare."
Subsequent to listing, the Convalo Board of Directors approved the issuance of performance stock compensation in the form of options to several key personnel. Convalo issued (a) 3,000,000 options each to Michael Dalsin and Roger Greene as Chairman and CEO and Vice Chairman, respectively; (b) 500,000 options to Nitin Kaushal as non-executive Director; (c) 250,000 options to David Costine as non-executive Director; and (d) 100,000 options to Dennis Wilson as VP of Corporate Affairs. All options vest equally over three years at a market strike price of $0.55.
Convalo currently has 198,996,353 issued and outstanding common shares and 2,344,635 performance stock options available and yet-to-be assigned.
Convalo anticipates that the expiry date of the warrants outstanding exercisable for 43,125,000 common shares of Convalo at $0.50 per share, will be accelerated to November 11, 2015 pursuant to the terms of the Warrant Certificates. The acceleration is a result of Convalo's share price achieving a volume-weighted average trading price greater than $0.60 for 20 consecutive trading days since closing. The warrants were originally issued pursuant to Convalo's bought deal private placement of 43,125,000 units (each unit consisting of one common share and one warrant), for gross proceeds of $17,250,000, which closed on April 22, 2015.
Quelle: http://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aCXV-22799…
Convalo Health International Corp. has come to terms to acquire two profitable Southern California companies, Hollywood Detox Center and Accredited Rehab and Treatment Services (ARTS). As part of the acquisitions, Convalo will retain the three top executives in key positions at the national level, strengthening Convalo's existing management team in the area of operations, admissions and executive management. As part of the acquisition, these executives would take over operational management of the current BLVD Treatment Centers portfolio of outpatient centers.
The acquisitions, expected to close very shortly pending a final purchase agreement, provide a fully vertically integrated platform in Hollywood and, within the next year, serve as a platform for the greater Los Angeles metropolitan area, offering detox services, men's and women's residential treatment services and aftercare services in West Los Angeles subsequent to Convalo's acquisition last month of the outpatient center announced March 30th, 2015.
For the Hollywood area, the acquisition will immediately give Convalo the ability to provide services that fully encompass the entirety of the patients' needs throughout the course of recovery, resulting in improvements to overall quality of care, a higher revenue per patient, and a more fluid patient experience at every level.
The accretive acquisitions will have an immediate and positive impact on earnings per share (EPS). The final terms of the acquisitions will be announced upon the execution of the final purchase agreements. The sellers will take both stock and cash as consideration.
"With this deal, we have a full service platform in Los Angeles," said Michael Dalsin, Chairman of Convalo. "We wanted to announce this deal pre-closing to ensure that the respective staff members at BLVD Centers, ARTS and Hollywood Detox could openly work together to integrate and begin cross selling all services to clients. We plan to announce full financial details of the acquisition at closing, both in terms of expected positive impact on our annual revenues and profits, as well as the amount of cash and restricted stock paid to the sellers."
"We are particularly excited to be retaining Keith Fowler and Brent Ortner from Hollywood Detox and Ryan Newport from ARTS as senior executives of our nationwide strategy and I welcome them as future shareholders and partners in our acquisition model. We expect to have a substantial amount of cash after we close this deal and are focusing on deals in New York, San Francisco, Miami and Chicago to create a nationwide network of addiction treatment centers offering the full range of addiction services from detox all the way to aftercare."
Subsequent to listing, the Convalo Board of Directors approved the issuance of performance stock compensation in the form of options to several key personnel. Convalo issued (a) 3,000,000 options each to Michael Dalsin and Roger Greene as Chairman and CEO and Vice Chairman, respectively; (b) 500,000 options to Nitin Kaushal as non-executive Director; (c) 250,000 options to David Costine as non-executive Director; and (d) 100,000 options to Dennis Wilson as VP of Corporate Affairs. All options vest equally over three years at a market strike price of $0.55.
Convalo currently has 198,996,353 issued and outstanding common shares and 2,344,635 performance stock options available and yet-to-be assigned.
Convalo anticipates that the expiry date of the warrants outstanding exercisable for 43,125,000 common shares of Convalo at $0.50 per share, will be accelerated to November 11, 2015 pursuant to the terms of the Warrant Certificates. The acceleration is a result of Convalo's share price achieving a volume-weighted average trading price greater than $0.60 for 20 consecutive trading days since closing. The warrants were originally issued pursuant to Convalo's bought deal private placement of 43,125,000 units (each unit consisting of one common share and one warrant), for gross proceeds of $17,250,000, which closed on April 22, 2015.
Quelle: http://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aCXV-22799…
Convalo Health International Corp. has been halted at 8:02 a.m. PT on June 10, 2015, at the company's request, pending news.
CONVALO EXECUTES FINAL BINDING PURCHASE AGREEMENTS FOR HOLLYWOOD DETOX AND ARTS; INCREASES RUN RATE REVENUES TO OVER $23 MILLION AND ADJUSTED EBITDA TO OVER $5.5 MILLION
Convalo Health International Corp. has executed final binding purchase agreements for the acquisition of Hollywood Detox Center and Accredited Rehab and Treatment Services (ARTS), two profitable Southern California companies.
Hollywood Detox and ARTS are behavioral health facilities offering detox and residential treatment services for both men and woman in and around the Hollywood and central Los Angeles area.
When added to the outpatient treatment services currently offered by BLVD Treatment Centers, Convalo now has a full service behavioral health platform spanning Hollywood and Central Los Angeles capable of treating patients at every level of the addiction treatment continuum. The combined annual revenue run-rate for this Hollywood and Central Los Angeles business now exceeds $23,000,000 and annualized run rate Adjusted EBITDA now exceeds $5,500,000.
By the end of the year, Convalo will expand this platform to include additional detox and residential treatment centers for both men and women on the west side of Los Angeles.
Three of the companies' top level executives, Keith Fowler, Brent Ortner and Ryan Newport, will remain on after the transaction and are expected to play key roles in Convalo moving forward.
Terms of the Acquisition
Management has reported combined trailing 12-month revenues in excess of $14 million and Adjusted EBITDA in excess of $3.6 million. This acquisition is expected to increase Convalo's revenues by over 150% and Adjusted EBITDA by more than 220%.
According to the Purchase Agreements, Convalo will acquire the businesses for a mix of cash and stock. Convalo will pay a total of $7,937,500 in cash and up to 8,000,000 shares or under 3% of the fully diluted shares of the company. Post-acquisition, Convalo will have over $21,500,000 in cash on the balance sheet with which to make further acquisitions. Convalo has no debt.
"We are now a fully established addiction services company in the heart of Los Angeles with over $23 million in revenues and significant profitability" said Mr. Dalsin, Chairman and CEO of Convalo. "While there is a significant positive impact on revenue and profits, this acquisition really only covers Hollywood and Central Los Angeles. The acquisition of the management team gives us the ability to create a similar business in terms of revenues and profits in West Los Angeles and in San Francisco this year."
"When closed, this acquisition will be EPS accretive," continued Mr. Dalsin. "We continue to invest heavily in our M&A activities and continue to expect to close deals in other major U.S. cities in the near future."
Quelle: http://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aCXV-22868…
Convalo Health International Corp. has executed final binding purchase agreements for the acquisition of Hollywood Detox Center and Accredited Rehab and Treatment Services (ARTS), two profitable Southern California companies.
Hollywood Detox and ARTS are behavioral health facilities offering detox and residential treatment services for both men and woman in and around the Hollywood and central Los Angeles area.
When added to the outpatient treatment services currently offered by BLVD Treatment Centers, Convalo now has a full service behavioral health platform spanning Hollywood and Central Los Angeles capable of treating patients at every level of the addiction treatment continuum. The combined annual revenue run-rate for this Hollywood and Central Los Angeles business now exceeds $23,000,000 and annualized run rate Adjusted EBITDA now exceeds $5,500,000.
By the end of the year, Convalo will expand this platform to include additional detox and residential treatment centers for both men and women on the west side of Los Angeles.
Three of the companies' top level executives, Keith Fowler, Brent Ortner and Ryan Newport, will remain on after the transaction and are expected to play key roles in Convalo moving forward.
Terms of the Acquisition
Management has reported combined trailing 12-month revenues in excess of $14 million and Adjusted EBITDA in excess of $3.6 million. This acquisition is expected to increase Convalo's revenues by over 150% and Adjusted EBITDA by more than 220%.
According to the Purchase Agreements, Convalo will acquire the businesses for a mix of cash and stock. Convalo will pay a total of $7,937,500 in cash and up to 8,000,000 shares or under 3% of the fully diluted shares of the company. Post-acquisition, Convalo will have over $21,500,000 in cash on the balance sheet with which to make further acquisitions. Convalo has no debt.
"We are now a fully established addiction services company in the heart of Los Angeles with over $23 million in revenues and significant profitability" said Mr. Dalsin, Chairman and CEO of Convalo. "While there is a significant positive impact on revenue and profits, this acquisition really only covers Hollywood and Central Los Angeles. The acquisition of the management team gives us the ability to create a similar business in terms of revenues and profits in West Los Angeles and in San Francisco this year."
"When closed, this acquisition will be EPS accretive," continued Mr. Dalsin. "We continue to invest heavily in our M&A activities and continue to expect to close deals in other major U.S. cities in the near future."
Quelle: http://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aCXV-22868…
ist da jemand?
kann ja ned sein das sonst niemand eine company mit solchen zahlen am radar hat
kann ja ned sein das sonst niemand eine company mit solchen zahlen am radar hat
Antwort auf Beitrag Nr.: 50.507.112 von lichtleicht am 28.08.15 08:23:18
Außerdem sieht es gerade gefährlich nach Bärenmarkt aus.
Auf der ganzen Welt sind die Börsen schon gecrasht. Alle Währungen der Rohstoffexportierenden Länder sind gecrasht, deren Börsen auch.
Nur die großen Aktienmärkte der Industrienationen halten sich noch.
Es könnte bald echt bergab gehen.
Also Vorsicht! Nicht zu viel riskieren!
Kauf Dir zusätzlich für 100 oder 200 EURO Zertis mit 3 oder 4-fach Hebel als Absicherung gegen einen Crash. Mit etwas Glück können die am Ende das 10-fache wert sein. Nutze aber auf keinen Fall nen größeren Hebel, denn sonst sind die ganzen Gewinne gleich wieder weg, wenn es mal eine Bärenmarktrally gibt.
Viel Glück.
Desinteresse
Das liegt daran, dass es erstens ne kleine kanadische Firma ist. Man kann auch nicht direkt handeln.Außerdem sieht es gerade gefährlich nach Bärenmarkt aus.
Auf der ganzen Welt sind die Börsen schon gecrasht. Alle Währungen der Rohstoffexportierenden Länder sind gecrasht, deren Börsen auch.
Nur die großen Aktienmärkte der Industrienationen halten sich noch.
Es könnte bald echt bergab gehen.
Also Vorsicht! Nicht zu viel riskieren!
Kauf Dir zusätzlich für 100 oder 200 EURO Zertis mit 3 oder 4-fach Hebel als Absicherung gegen einen Crash. Mit etwas Glück können die am Ende das 10-fache wert sein. Nutze aber auf keinen Fall nen größeren Hebel, denn sonst sind die ganzen Gewinne gleich wieder weg, wenn es mal eine Bärenmarktrally gibt.
Viel Glück.
Antwort auf Beitrag Nr.: 50.576.486 von NicTheMagician am 08.09.15 08:13:50
Aber auch damit Vorsicht, denn letztes Jahr gab es nach Oktober nen Shortsqueeze. Deshalb hat es noch einmal so angezogen.
Falls es noch einmal nen Shortsqueeze gibt, einfach nächsten Jahr neue ZErtis kaufen. Irgendwann müssen wir ja oben angekommen sein.
Zertis
Ich meine Short-Zertifikate mit Hebel auf die großen Indices.Aber auch damit Vorsicht, denn letztes Jahr gab es nach Oktober nen Shortsqueeze. Deshalb hat es noch einmal so angezogen.
Falls es noch einmal nen Shortsqueeze gibt, einfach nächsten Jahr neue ZErtis kaufen. Irgendwann müssen wir ja oben angekommen sein.
CONVALO HEALTH INTERNATIONAL HIGHLIGHTS RECORD REVENUE AND EBITDA FOR THE QUARTER ENDING AUGUST 31, 2015
Convalo Health International Corp. has had a record quarter of revenue and adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) for the quarter ending Aug. 31, 2015.
Total quarterly revenue exceeded $5.6-million, as compared with revenue of $2.3-million for the previous quarter ending May 31, 2015, a 145-per-cent growth rate quarter over quarter and an annualized growth rate of over 580 per cent. This quarter included only two months of revenue from the acquisition of Hollywood Detox and Accredited Rehab and Treatment Services.
September annualized run-rate revenue is expected to exceed $30-million.
Adjusted EBITDA rose to over $1-million for the quarter, an increase of more than 127 per cent from the previous quarter. Excluding corporate overhead, such as public company cost, operating margins were in excess of 22 per cent.
Full results are expected to be posted on SEDAR before their due date of Oct. 31, 2015. The Convalo management team will hold an earnings call to review the quarter in detail in early November.
Cash on the balance sheet as of Sept. 15, 2015, was $24-million.
"This quarter is a turning point for Convalo," said Michael Dalsin, chairman of Convalo Health International. "Two of the three months of this quarter represent a fully integrated addiction services company, or what we call a pod, in the heart of Los Angeles. That includes a detox centre, a men's and women's residential centre, and an outpatient centre. We have finally moved from the start-up phase to the fast-growth phase of this company. We have systematized our growth plan, bolstered our executive team and have visibility into the next few years of our business. We have launched our second pod in west Los Angeles and expect to launch our third pod in San Francisco very soon. I expect the impact of these investments to be reflected in next quarter's financials.
"Most gratifying of all, this quarter, and the subsequent month since, has proven our investment thesis. We can launch a pod with a limited capital investment and create a high-margin, vertically integrated business that can get to full capacity in a very short period of time; in the case of central Los Angeles, under one year. The result is a very high return on equity. We have over $24-million in cash on the balance sheet, which is certainly enough, without debt, to launch four additional pods in other cities around the United States. I expect each pod can generate significant revenue and earnings under the current reimbursement rates. I believe we are at the beginning of a huge market expansion and I expect that in the next 18 months, we will be able to launch these additional pods while the market is still young, maximizing our operating margins."
Pursuant to the news release dated May 20, 2015, Convalo has confirmed that the expiry date of the warrants outstanding, exercisable for 43,125,000 common shares of Convalo at 50 cents per share, will be accelerated to Nov. 11, 2015, pursuant to the terms of the warrant certificates. The acceleration is a result of Convalo's share price achieving a volume-weighted average trading price greater than 60 cents for 20 consecutive trading days around the time of closing of the Hollywood Detox Center and Accredited Rehab and Treatment Services acquisition, which was announced on May 20, 2015. The warrants were originally issued pursuant to Convalo's bought-deal private placement of 43,125,000 units (with each unit consisting of one common share and one warrant) for gross proceeds of $17.25-million, which closed on April 22, 2015.
Quelle: http://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aCXV-23146…
Convalo Health International Corp. has had a record quarter of revenue and adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) for the quarter ending Aug. 31, 2015.
Total quarterly revenue exceeded $5.6-million, as compared with revenue of $2.3-million for the previous quarter ending May 31, 2015, a 145-per-cent growth rate quarter over quarter and an annualized growth rate of over 580 per cent. This quarter included only two months of revenue from the acquisition of Hollywood Detox and Accredited Rehab and Treatment Services.
September annualized run-rate revenue is expected to exceed $30-million.
Adjusted EBITDA rose to over $1-million for the quarter, an increase of more than 127 per cent from the previous quarter. Excluding corporate overhead, such as public company cost, operating margins were in excess of 22 per cent.
Full results are expected to be posted on SEDAR before their due date of Oct. 31, 2015. The Convalo management team will hold an earnings call to review the quarter in detail in early November.
Cash on the balance sheet as of Sept. 15, 2015, was $24-million.
"This quarter is a turning point for Convalo," said Michael Dalsin, chairman of Convalo Health International. "Two of the three months of this quarter represent a fully integrated addiction services company, or what we call a pod, in the heart of Los Angeles. That includes a detox centre, a men's and women's residential centre, and an outpatient centre. We have finally moved from the start-up phase to the fast-growth phase of this company. We have systematized our growth plan, bolstered our executive team and have visibility into the next few years of our business. We have launched our second pod in west Los Angeles and expect to launch our third pod in San Francisco very soon. I expect the impact of these investments to be reflected in next quarter's financials.
"Most gratifying of all, this quarter, and the subsequent month since, has proven our investment thesis. We can launch a pod with a limited capital investment and create a high-margin, vertically integrated business that can get to full capacity in a very short period of time; in the case of central Los Angeles, under one year. The result is a very high return on equity. We have over $24-million in cash on the balance sheet, which is certainly enough, without debt, to launch four additional pods in other cities around the United States. I expect each pod can generate significant revenue and earnings under the current reimbursement rates. I believe we are at the beginning of a huge market expansion and I expect that in the next 18 months, we will be able to launch these additional pods while the market is still young, maximizing our operating margins."
Pursuant to the news release dated May 20, 2015, Convalo has confirmed that the expiry date of the warrants outstanding, exercisable for 43,125,000 common shares of Convalo at 50 cents per share, will be accelerated to Nov. 11, 2015, pursuant to the terms of the warrant certificates. The acceleration is a result of Convalo's share price achieving a volume-weighted average trading price greater than 60 cents for 20 consecutive trading days around the time of closing of the Hollywood Detox Center and Accredited Rehab and Treatment Services acquisition, which was announced on May 20, 2015. The warrants were originally issued pursuant to Convalo's bought-deal private placement of 43,125,000 units (with each unit consisting of one common share and one warrant) for gross proceeds of $17.25-million, which closed on April 22, 2015.
Quelle: http://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aCXV-23146…
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -1,30 | |
| -4,22 | |
| -2,73 | |
| 0,00 | |
| 0,00 | |
| -0,29 | |
| +0,42 | |
| 0,00 | |
| -32,00 | |
| -2,97 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 204 | ||
| 190 | ||
| 155 | ||
| 68 | ||
| 32 | ||
| 29 | ||
| 28 | ||
| 26 | ||
| 26 | ||
| 25 |
